Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia
Alector, Inc. (ALEC)
Last alector, inc. earnings: 3/24 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and enrollment for the INFRONT Phase 2 clinical trial for its product candidate AL001. AL001 is being evaluated for the treatment of people with frontotemporal dementia (FTD) with specific genetic mutations, including the granulin gene (FTD-GRN). “We are encouraged by the recent data from our Phase 1b trial of AL001, in which AL001 was well-tolerated and restored progranulin back to normal physiological levels in the central nervous system of FTD-GRN patients,” said Robert Paul, M.D, Ph.D., chief medical officer of Alector. “In this Phase 2 trial, we plan to enroll up to 32 patients and gain important insights into AL001’s safety and activity in this patient population as we prepare for our pivotal Phase 3 study in 2020.” The Phase 2 trial will assess the longitudinal sa
Show less
Read more
Impact Snapshot
Event Time:
ALEC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALEC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALEC alerts
High impacting Alector, Inc. news events
Weekly update
A roundup of the hottest topics
ALEC
News
- Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules CapitalGlobeNewswire
- Alector, Inc. (NASDAQ: ALEC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- Alector Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)GlobeNewswire
- Alector, Inc. (NASDAQ: ALEC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
ALEC
Earnings
- 11/6/24 - Beat
ALEC
Sec Filings
- 11/14/24 - Form 8-K
- 11/12/24 - Form SC
- 11/7/24 - Form SC
- ALEC's page on the SEC website